Application of bioluminescence imaging to the prediction of lethality in vaccinia virus-infected mice

Journal of Virology

Volumn 83, Issue 20, 2009, Pages 10437-10447

  Zaitseva, Marina ^a   Kapnick, Senta M ^a   Scott, John ^a   King, Lisa R ^a   Manischewitz, Jody ^a   Sirota, Lev ^a   Kodihalli, Shantha ^b   Golding, Hana ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b Cangene Corporation   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LUCIFERASE; SMALLPOX VACCINE; VACCINIA ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG EFFICACY; FEMALE; IMMUNITY; IMMUNIZATION; LETHALITY; LIVER; MOUSE; NONHUMAN; NOSE CAVITY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SMALLPOX; SPLEEN; SURVIVAL; VACCINIA; VACCINIA VIRUS; VIRUS RECOMBINANT; WEIGHT REDUCTION;

ANIMALS; FEMALE; LIVER; LUCIFERASES, FIREFLY; LUMINESCENT MEASUREMENTS; LUNG; MICE; MICE, INBRED BALB C; PREDICTIVE VALUE OF TESTS; RECOMBINATION, GENETIC; SURVIVAL ANALYSIS; VACCINIA; VACCINIA VIRUS;

ANIMALIA; MUS; VACCINIA VIRUS;

EID: 70349742556     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01296-09     Document Type: Article

References (27)

1. Amanna, I. J., M. K. Slifka, and S. Crotty. 2006. Immunity and immunological memory following smallpox vaccination. Immunol. Rev. 211:320-337.
2. Belongia, E. A., and A. L. Naleway. 2003. Smallpox vaccine: the good, the bad, and the ugly. Clin. Med. Res. 1:87-92.
3. Bray, M., and C. J. Roy. 2004. Antiviral prophylaxis of smallpox. J. Antimicrob. Chemother. 54:1-5.
4. Cangene Corporation. 2005. Vaccinia immune globulin intervenous human (VIGIV) package insert. Cangene Corporation, Winnipeg, Manitoba, Canada. http: //www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts /LicensedProductsBLAS/FractionatedPlasmaProducts/ucm179513.htm.
5. Cosma, A., R. Nagaraj, C. Staib, C. Diemer, F. Wopfner, H. Schatzl, D. H. Busch, G. Sutter, F. D. Goebel, and V. Erfle. 2007. Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAART. AIDS Res. Hum Retrovir. 23:782-793.
6. Edghill-Smith, Y., H. Golding, J. Manischewitz, L. R. King, D. Scott, M. Bray, A. Nalca, J. W. Hooper, C. A. Whitehouse, J. E. Schmitz, K. A. Reimann, and G. Franchini. 2005. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat. Med. 11:740-747.
7. Gherardi, M. M., and M. Esteban. 1999. Mucosal and systemic immune responses induced after oral delivery of vaccinia virus recombinants. Vaccine 17:1074-1083.
8. Goldsmith, J. C., N. Eller, M. Mikolajczyk, J. Manischewitz, H. Golding, and D. E. Scott. 2004. Intravenous immunoglobulin products contain neutralizing antibodies to vaccinia. Vox Sang. 86:125-129.
9. Gomez, C. E., J. L. Najera, E. Domingo-Gil, L. Ochoa-Callejero, G. Gonzalez-Aseguinolaza, and M. Esteban. 2007. Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice. J. Gen. Virol. 88:2473-2478.
10. Gonen, M. 2007. Analyzing receiver operating characteristic curves using SAS. SAS Press, Cary, NC.
11. Greenberg, R. N., and J. S. Kennedy. 2008. ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine. Exp. Opin. Investig. Drugs 17:555-564.
12. Gurt, I., I. Abdalrahman, and E. Katz. 2006. Pathogenicity and immunogenicity in mice of vaccinia viruses mutated in the viral envelope proteins A33R and B5R. Antivir. Res. 69:158-164.
13. Hammarlund, E., M. W. Lewis, S. G. Hansen, L. I. Strelow, J. A. Nelson, G. J. Sexton, J. M. Hanifin, and M. K. Slifka. 2003. Duration of antiviral immunity after smallpox vaccination. Nat. Med. 9:1131-1137.
14. Harrison, S. C., B. Alberts, E. Ehrenfeld, L. Enquist, H. Fineberg, S. L. McKnight, B. Moss, M. O'Donnell, H. Ploegh, S. L. Schmid, K. P. Walter, and J. Theriot. 2004. Discovery of antivirals against smallpox. Proc. Natl. Acad. Sci. USA 101:11178-11192.
15. Hooper, J. W., E. Thompson, C. Wilhelmsen, M. Zimmerman, M. A. Ichou, S. E. Steffen, C. S. Schmaljohn, A. L. Schmaljohn, and P. B. Jahrling. 2004. Smallpox DNA vaccine protects nonhuman primates against lethal monkey-pox. J. Virol. 78:4433-4443.
16. Hutchens, M., and G. D. Luker. 2007. Applications of bioluminescence imaging to the study of infectious diseases. Cell Microbiol. 9:2315-2322. (Pubitemid 47365638)
17. Koszinowski, U., and R. Thomssen. 1975. Target cell-dependent T cell-mediated lysis of vaccinia virus-infected cells. Eur. J. Immunol. 5:245-251.
18. Luker, K. E., M. Hutchens, T. Schultz, A. Pekosz, and G. D. Luker. 2005. Bioluminescence imaging of vaccinia virus: effects of interferon on viral replication and spread. Virology 341:284-300.
19. Luker, K. E., and G. D. Luker. 2008. Applications of bioluminescence imaging to antiviral research and therapy: multiple luciferase enzymes and quantitation. Antivir. Res. 78:179-187.
20. Meseda, C. A., A. D. Garcia, A. Kumar, A. E. Mayer, J. Manischewitz, L. R. King, H. Golding, M. Merchlinsky, and J. P. Weir. 2005. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model. Virology 339:164-175.
21. Panchanathan, V., G. Chaudhri, and G. Karupiah. 2007. Correlates of protective immunity in poxvirus infection: where does antibody stand? Immunol. Cell Biol. 86:80-86.
22. Parrino, J., and B. S. Graham. 2006. Smallpox vaccines: past, present, and future. J. Allergy Clin. Immunol. 118:1320-1326.
23. Ramirez, J. C., M. M. Gherardi, and M. Esteban. 2000. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J. Virol. 74:923-933.
24. Rodriguez, J. F., D. Rodriguez, J. R. Rodriguez, E. B. McGowan, and M. Esteban. 1988. Expression of the firefly luciferase gene in vaccinia virus: a highly sensitive gene marker to follow virus dissemination in tissues of infected animals. Proc. Natl. Acad. Sci. USA 85:1667-1671.
25. Townsley, A. C., A. S. Weisberg, T. R. Wagenaar, and B. Moss. 2006. Vaccinia virus entry into cells via a low-pH-dependent endosomal pathway. J. Virol. 80:8899-8908. (Pubitemid 44359964)
26. Williamson, J. D., R. W. Reith, L. J. Jeffrey, J. R. Arrand, and M. Mackett. 1990. Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory route. J. Gen. Virol. 71:2761-2767.
27. Wittek, R. 2006. Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy. Int. J. Infect. Dis. 10:193-201.